| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Dicot Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0086 |
| 52 Week High | SEK 0.042 |
| 52 Week Low | SEK 0.003 |
| Beta | 1.47 |
| 11 Month Change | -36.76% |
| 3 Month Change | -67.30% |
| 1 Year Change | 7.50% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| KN0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -20.4% | -3.0% | -1.9% |
| 1Y | 7.5% | -13.2% | 12.3% |
Return vs Industry: KN0 exceeded the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: KN0 underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| KN0 volatility | |
|---|---|
| KN0 Average Weekly Movement | 37.3% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: KN0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: KN0's weekly volatility (37%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3 | Elin Trampe | www.dicotpharma.com |
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It is developing LIB-01 for the treatment of erectile dysfunction and premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024.
Dicot Pharma AB Fundamentals Summary
| KN0 fundamental statistics | |
|---|---|
| Market cap | €12.92m |
| Earnings (TTM) | -€4.48m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs KN0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KN0 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 50.94m |
| Earnings | -SEK 50.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | -0.062 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did KN0 perform over the long term?
See historical performance and comparison